Hey I am on Medial • 11m
I invested in three biotech IPOs during the COVID bubble. All of them had "revolutionary technology" and "massive TAM" stories. All three are down 70%+ from IPO price. The problem with biotech investing is that retail investors can't properly evaluate the technical claims or regulatory pathways. We're relying on management projections, which are always optimistic for IPOs. What concerns me about Molbio is the timing - they could have gone public during their COVID revenue peak but didn't. Why now? Likely because they've seen their peak and want to cash out while the story still sounds good. Hard pass from me.
Young mind. Bold cod... • 8m
A potential resurgence of COVID-19 appears to be a concern for many. If lockdown measures are reinstituted, it's important to prioritize two key areas: focus on developing your skills and career, and maintain your health. While the prospect of anothe
See MoreSoftware Engineer • 1y
RECESSION WARNING: US Leading Economic Index® (LEI) is down 14.7% from this economic cycle peak. In the last 65 years, such a drop happened only during recessions. Index takes into account, US labor market data, manufacturing sector data, building
See More
Download the medial app to read full posts, comements and news.